Complex Regional Pain Syndrome (CRPS) is a neuropathic disorder characterized by severe chronic pain, swelling, and hypersensitivity to touch. As a debilitating, orphan disease that is difficult to diagnose and treat, there is a strong unmet need for new, helpful treatment options.
Dr. Amol Soin, Founder and CEO of Soin Therapeutics, joins us to discuss his orphan drug status from the FDA for low-dose Naltrexone to treat complex regional pain syndrome. This is a non-addicting and non-sedating drug that could be a new way to treat complex regional pain syndrome. Low-dose naltrexone is currently being studied in clinical trials, as a step to achieve FDA approval.
We traveled to Dayton, Ohio, to meet Donna, a busy wife and mother whose life was put to a stop when she started experiencing symptoms. After being diagnosed with CRPS, Donna wants to help others manage this often complicated, invisible illness so they feel less alone.
BSST BACT 0036 1080P